


Pomalidomide-amido-PEG3-C2-NH2

Cat. No.:	HY-130521		
CAS No.:	2328070-52-4		
Molecular Formula:	C ₂₂ H ₂₈ N ₄ O ₈		
Molecular Weight:	476.48		
Target:	E3 Ligase Ligand-Linker Conjugates		
Pathway:	PROTAC		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (209.87 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.0987 mL	10.4936 mL	20.9872 mL
		5 mM	0.4197 mL	2.0987 mL	4.1974 mL
		10 mM	0.2099 mL	1.0494 mL	2.0987 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology ^[1] .
IC ₅₀ & Target	Cereblon
In Vitro	Pomalidomide-amido-PEG3-C2-NH2 (Compound 5b) can be used to synthesize BI-3663. BI-3663 (cereblon-based) degrades focal adhesion tyrosine kinase (PTK2) with a median DC ₅₀ of 30 nM to >80% across a panel of 11 human hepatocellular carcinoma (HCC) cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Popow J, et al. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. J Med Chem. 2019 Mar 14;62(5):2508-2520.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA